Penn Medicine’s Abramson Cancer Center and the Leukemia & Lymphoma Society P R E S E NT UPDATE IN HEMATOLOGIC CANCERS With Proceedings from International Medical Meetings REGISTER ONLINE AT PENNCANCER.ORG/CME/BLOOD CME/CE-Certified Course FR IDAY, JAN U ARY 3 0 , 2 0 1 5 8:00 A.M. – 4:00 P.M. Hub Cira Center 2929 Arch Street | Mezzanine Level Philadelphia, PA 19104 For directions and parking go to www.thehub.com/maps-cira.php Parking fees are not covered by this course. UPDATE IN HEMATOLOGIC CANCERS With Proceedings from International Medical Meetings FRIDAY, JANUARY 30 2015 8:00 A.M. – 4:00 P.M. HUB CIRA CENTER 2929 Arch Street Mezzanine Level Philadelphia, PA 19104 DIRECTIONS AND PARKING The Hub Cira Center is located at 2929 Arch Street, Mezzanine Level, Philadelphia, PA 19104. Directions and parking information can be found at www.thehub.com/maps-cira.php. Parking fees are not covered by this course. OVERVIEW This course is designed to be a comprehensive update of new treatment approaches recently incorporated into patient management, including the different types of hematologic malignancies and how clinicians should evolve therapeutic approaches based on factors, such as tumor classification and response. Penn faculty will discuss recent technological advances in blood cancers that will provide a perspective on clinical data presented at major international medical meetings. OBJECTIVES Upon completion of this course, participants should be able to: • Discuss clinical features, including differential diagnoses of the various hematologic malignancies • Describe recent advances in treatment for the various hematologic malignancies • Summarize the major patient management issues associated with hematologic malignancies • Identify and manage long-term and late-effects of treatment for hematologic cancers, including bone marrow transplant • Define the state-of-the-art for genomic analyses for hematologic malignancies • Apply new strategies for incorporating therapies that target metabolism in blood cancers WHO SHOULD ATTEND The target audience is hematologists, medical and radiation oncologists, primary care physicians, pathologists, hematology/oncology fellows, oncology nurses, oncology social workers, and other healthcare professionals involved in the treatment of patients with blood cancer. Please note that most of the conference materials will be available online. Please bring your electronic device to view presentations in real time. AGENDA 8:00 am 8:30 am Registration and Continental Breakfast Welcome and Introduction Chi V. Dang, MD, PhD Edward A. Stadtmauer, MD M OR NI NG S ESS I O N 8:40 am Hematologic Malignancies Translational Center of Excellence Edward A. Stadtmauer, MD Controversies and Updates in Multiple Myeloma Moderator: Edward A. Stadtmauer, MD 9:00 am Update on MGUS, Smoldering Myeloma and Amyloidosis Brendan M. Weiss, MD 9:20 am Experimental Therapies for Relapsed Myeloma Dan T. Vogl, MD 9:40 am Latest Transplant Approaches for Myeloma Adam D. Cohen, MD 10:00 am Panel Discussion with Question and Answer Session 10:15 am BREAK Moderator: Edward A. Stadtmauer, MD Panel: Adam D. Cohen, MD Dan T. Vogl, MD Brendan M. Weiss, MD Transplant and Cellular Therapies Moderator: David L. Porter, MD 10:30 am Graft versus Host Disease 10:50 am ellular Therapy for Blood Cancers C David L. Porter, MD 11:10 am S urvivorship after Hematopoietic Cell Transplantation Alison W. Loren, MD, MS 11:30 am anel Discussion with Question and Answer Session P Moderator: David L. Porter, MD Panel: Alison W. Loren, MD, MS Ran Reshef, MD, MSc 11:45 am LUNCH Ran Reshef, MD, MSc AF T E R NO O N S E SS I O N Updates on Treatment Strategies in Leukemia Moderator: Selina M. Luger, MD 12:45 pm Update in Treatment Strategies for Leukemia 1:05 pm Latest Treatments for Acute Lymphocytic Leukemia 1:25 pm 1:45 pm Alexander E. Perl, MD Noelle V. Frey MD, MSCE Latest Update in Myeloproliferative Disease Elizabeth O. Hexner, MD Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD 2:05 pm Panel Discussion with Question and Answer Session Moderator: Selina M. Luger, MD Panel: Alexander E. Perl, MD Noelle V. Frey, MD, MSCE Elizabeth O. Hexner, MD James K. Mangan, MD, PhD New Therapies and Current Management of Lymphomas Moderator: Stephen J. Schuster, MD 2:25 pm New Therapies and Current Management of Lymphomas Stephen J. Schuster, MD 2:45 pm Therapeutic Advances in Hodgkin Lymphoma Jakub Svoboda, MD 3:05 pm Aggressive Lymphomas Sunita D. Nasta, MD, FACP 3:25 pm Chronic Lymphocytic Leukemia Anthony R. Mato, MD, MSCE 3:45 pm Panel Discussion with Question and Answer Session Moderator: Stephen J. Schuster, MD Panel: Jakub Svoboda, MD Anthony R. Mato, MD, MSCE Sunita D. Nasta, MD, FACP 4:00 pm Evaluation and Adjourn SPEAKERS COURSE DIRECTOR Edward A. Stadtmauer, MD Professor, Medicine Chief, Hematologic Malignancies Section Division of Hematology Oncology Co-Leader, Hematologic Malignancies Research Program COURSE CO-DIRECTORS Selina M. Luger, MD Professor, Medicine Division of Hematology Oncology Director, Leukemia Program David L. Porter, MD Jodi Fisher Horowitz Professor of Leukemia Care Excellence Division of Hematology Oncology Director, Blood and Marrow Transplantation Stephen J. Schuster, MD Robert and Margarita Louis-Dreyfus Associate Professor of Chronic Lymphocytic Leukemia and Lymphoma Division of Hematology Oncology Director, Lymphoma Program and Lymphoma Translational Research PENN MEDICINE FACULTY Adam D. Cohen, MD Assistant Professor, Medicine Division of Hematology Oncology Chi V. Dang, MD, PhD John H. Glick, MD Abramson Cancer Center Director’s Professor of Medicine Director, Abramson Cancer Center Noelle V. Frey, MD, MSCE Assistant Professor, Medicine Division of Hematology Oncology Elizabeth O. Hexner, MD Assistant Professor, Medicine Division of Hematology Oncology Alison W. Loren, MD, MS Assistant Professor of Medicine Division of Hematology Oncology James K. Mangan, MD, PhD Assistant Professor, Medicine Division of Hematology Oncology Anthony R. Mato, MD Assistant Professor, Medicine Division of Hematology Oncology Director, Chronic Lymphocytic Leukemia Program Sunita D. Nasta, MD, FACP Assistant Professor, Medicine Division of Hematology Oncology Alexander E. Perl, MD Assistant Professor, Medicine Division of Hematology Oncology Ran Reshef, MD, MSc Assistant Professor, Medicine Division of Hematology Oncology Jakub Svoboda, MD Assistant Professor, Medicine Division of Hematology Oncology Dan T. Vogl, MD Assistant Professor, Medicine Division of Hematology Oncology Brendan M. Weiss, MD Assistant Professor, Medicine Division of Hematology Oncology REGISTRATION The registration fee for practicing physician is $100.00. For non-Penn resident, fellow, nurse, and other healthcare professional, the fee is $50.00. For faculty, staff, resident, fellow and/or student of the University of Pennsylvania, the fee is $50.00. We accept Visa, Discover, MasterCard, and American Express. Registration includes breakfast, lunch, breaks and online course syllabus. R E G I S TE R O N L I N E AT PennCancer.org/CME/Blood ACCREDITATION AND DESIGNATION OF CREDIT HOSTING DEPARTMENT Update in Hematologic Cancers: with Proceedings from International Medical Meetings is hosted by the Abramson Cancer Center of the University of Pennsylvania and The Leukemia & Lymphoma Society. ACCREDITATION The Perelman School of Medicine at the University of Pennsylvania is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. DESIGNATION OF CREDIT PHYSICIANS: The Perelman School of Medicine at the University of Pennsylvania designates this live activity for a maximum of 6 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. AAPA: AAPA accepts certificates of participation for educational activities certified for Category 1 credit from AOACCME, prescribed credit from AAFP, and AMA PRA Category 1 Credit™. NURSES AND SOCIAL WORKERS: Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under provider number CEP 5832 to award 6.5 continuing education contact hour(s) through the California Board of Registered Nursing. The Leukemia & Lymphoma Society (LLS), provider number 1105, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org Approved Continuing Education Program (ACE). Approval Period: 12/2014 to 12/2017. LLS maintains responsibility for the program. Social workers should contact their regulatory board to determine course approval. Social workers will receive 6.5 CE clinical clock hour(s). DISCLOSURES The Perelman School of Medicine at the University of Pennsylvania, Office of Continuing Medical Education, adheres to the ACCME Standards for Commercial Support. Faculty disclosures information will be made available in the conference materials and syllabi. Faculty members are also expected to disclose to participants any discussion of off-label and/ or investigational use of pharmaceutical products or devices within their presentations. CANCELLATION POLICY In order to process refunds for course withdrawals, cancellations must be received in writing by January 16, 2015 and are subject to a service charge equivalent to 10% of the registration fee. No refunds will be issued thereafter. The University reserves the right to cancel or postpone this course due to unforeseen circumstances. In the event of a cancellation or postponement, the University will refund registration fees but is not responsible for related costs or expenses to participants, including cancellation fees assessed by hotels, airlines, and travel agencies. SERVICES FOR THE DISABLED If special arrangements are required for an individual with a disability to attend this course, please contact Barbara Lopez at [email protected] or 215-614-1954 no later than January 16, 2015. NONDISCRIMINATION STATEMENT The University of Pennsylvania values diversity and seeks talented students, faculty, and staff from diverse backgrounds. The University of Pennsylvania does not discriminate on the basis of race, sex, sexual orientation, gender identity, religion, color, national or ethnic origin, age, disability, or status as a Vietnam Era Veteran or disabled veteran in the administration of educational policies, programs or activities; admission policies; scholarship and loan awards; athletic, or other University administered programs or employment. Questions or complaints regarding this policy should be directed to Executive Director, Office of Affirmative Action and Equal Opportunity Programs, 3600 Chestnut Street, Sansom Place East Suite 228, Philadelphia, PA 19104-6106 or 215-898-6993 (Voice) or 215-898-7803 (TDD). www.upenn.edu/affirm-action. 8:00 A.M. – 4:00 P.M. FRIDAY, JANUARY 30, 2015 CME/CE-Certified Course With Proceedings from International Medical Meetings UPDATE IN HEMATOLOGIC CANCERS 3600 Market Street Suite 210 Philadelphia, PA 19104-2643 Permit No. 2563 Phila, PA 19176 PAID PRESORTED First Class Mail U.S. Postage